Skip to main content

Blood therapy giant CSL reports better than expected NPAT | CSL (ASX:CSL) Reporting Results

Jessica Amir
August 18, 2021

The biggest blood therapy company in the world and the second biggest vaccine company, CSL (ASX:CSL) reported its FY21 results.

CSL reported its NPAT jumped 13% to US$2.375 billion. This is 2% above market expectations. Profit growth was boosted by CSL’s Seqirus division, its flu vaccine business, which saw a 30% revenue boost. However, CSL’s Behring division, its blood therapy business, was severely impacted by COVID-19 restrictions.

CSL’s group revenue rose 13% to US$10.3 billion, while CSL’s cashflow from operations surged 46% to US$3.6 billion.

CSL declared a final dividend of US$1.18ps (AU$1.61ps), payable on 30th September. CSL’s total full year dividends increased 10% to US$2.22 per share.

CSL’s FY22 outlook views profit to fall between US$2.15 billion to US$2.25 billion.

CSL is a Morgan Stanley, Macquarie, Citi and Credit Suisse HOLD stock. UBS and Morgans have CSL as a BUY stock.

CSL shares surged to $302.80, at its highest level since June. However, traders quickly took profits, and CSL is now trading at $294.83.

Morning Bell 18 May

Sophia Mavridis
May 18, 2022

Morning Bell 17 May

Sophia Mavridis
May 17, 2022

Morning Bell 16 May

Paulina Peters
May 16, 2022

Weekly Wrap 13 May

Sophia Mavridis
May 13, 2022

Morning Bell 12 May

Paulina Peters
May 12, 2022

Morning Bell 11 May

Sophia Mavridis
May 11, 2022

Morning Bell 10 May

Paulina Peters
May 10, 2022

Morning Bell 9 May

Sophia Mavridis
May 9, 2022

Weekly Wrap 6 May

Sophia Mavridis
May 6, 2022

Morning Bell 5 May

Paulina Peters
May 5, 2022

Morning Bell 4 May

Sophia Mavridis
May 4, 2022

Morning Bell 3 May

Paulina Peters
May 3, 2022